Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 84. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Nirogacestat effective in desmoid tumours1061
Enfortumab vedotin is safe and effective721
HSCT prolongs remission of high-risk CTCLs717
Whole-genome sequencing for myeloid disease: one assay to stratify them all?686
Combination improves salvage outcomes611
Emerging clinical applications of single-cell RNA sequencing in oncology578
Thermal ablation is safer than resection of colorectal liver lesions563
SOX superior to CAPOX in resectable G/GEJ cancer550
Hodgkin lymphoma: great progress with room for improvement528
Practicing on the edge of oncology: when standard of care feels uncomfortable517
Tabelecleucel is effective in EBV-positive lymphoproliferative disease512
Copanlisib safe and active in combination509
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer509
New insights from recurrence score455
Promising OS with oncolytic virotherapy454
Adjuvant pembrolizumab improves overall survival in patients with RCC434
Novel ICI–TKI combination improves HCC outcomes422
Uncovering adagrasib resistance417
Cemiplimab is a new option in BCC376
Adjuvant pembrolizumab shows promise328
BrECADD raises the bar in classical Hodgkin lymphoma326
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer317
Capivasertib delays disease progression316
HSP90 inhibition improves GIST survival309
Tasadenoturev active in DIPG307
From ASCO 2023306
Abemaciclib crowned in monarchE299
GPRC5D-CAR T cells active in MM283
Dabrafenib–trametinib moves to the first line in low-grade glioma270
Efficacy of TILs confirmed269
Promise with co-administration of CAR T cells265
A new standard of care for advanced-stage urothelial carcinoma247
Pegargiminase improves outcomes in nonepithelioid MPM245
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC242
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC236
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care233
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes233
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer229
From little subclones grow mighty oaks215
Finding the Goldilocks zone in neoadjuvant radioimmunotherapy202
Adjuvant olaparib — should all patients with breast cancer have genetic testing?198
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy195
Is NETTER-2 a practice-changing trial?194
Should the control arms of randomized trials have an expiry date?189
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks189
Applications of cell therapy in the treatment of virus-associated cancers188
HPV-associated oropharyngeal cancer — discussion points188
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’183
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma182
A new era for glioma therapy — targeting mutant IDH179
CAR T cells in multiple myeloma: lessons learned176
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies166
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis165
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood164
Cerebrospinal fluid liquid biopsies for medulloblastoma158
Immunotherapy approaches for malignant pleural mesothelioma157
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent152
Anaplastic glioma: benefit of temozolomide clarified150
Gut microbes as biomarkers of ICI response — sharpening the focus150
From ASCO 2022146
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety140
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome140
Functional precision oncology using patient-derived assays: bridging genotype and phenotype134
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe133
International approvals of cilta-cel: a lens on CAR T cell regulation133
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma129
Nucleic acid-based drugs for patients with solid tumours126
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer124
Targeting cuproplasia and cuproptosis in cancer109
Molecular tumour boards — current and future considerations for precision oncology108
Beneficial autoimmunity improves cancer prognosis103
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders101
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer99
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime97
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management97
Nasopharyngeal carcinoma: an evolving paradigm97
The immune landscape of common CNS malignancies: implications for immunotherapy96
New treatment strategies for advanced-stage gastrointestinal stromal tumours95
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination95
KEYNOTE-355 — OS benefit now reported92
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion91
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma88
Gut microbiota in colorectal cancer development and therapy86
The emerging roles of circRNAs in cancer and oncology84
Exploring the next generation of antibody–drug conjugates84
0.081212043762207